



# Reblozyl in Saudi Arabia

*The SFDA named-patient coordination pathway — indicative 2026*

HEMATOLOGY · BETA-THALASSEMIA & LOWER-RISK MDS ANAEMIA

## The clinical situation

Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation agent, FDA-approved for anaemia in adults with transfusion-dependent beta-thalassemia and for anaemia in lower-risk myelodysplastic syndromes (MDS) requiring transfusions. Manufactured by Bristol Myers Squibb, it is a fusion protein that binds TGF- $\beta$  superfamily ligands and promotes late-stage red-blood-cell maturation, reducing transfusion burden in appropriately selected patients. Beta-thalassemia has a meaningful disease burden in parts of Saudi Arabia. Delivered as a subcutaneous injection every three weeks, weight-based. Carries warnings related to thromboembolism and hypertension.

## The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist confirms diagnosis (beta-thalassemia genotype with transfusion dependence, or MDS with ring sideroblasts / SF3B1 mutation), baseline labs, and transfusion history.
- 2 SFDA named-patient application.** Physician files dossier: clinical letter, patient reference, product details, three-weekly SC dosing plan.
- 3 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 4 Cold-chain shipment.** Reblozyl ships at 2–8°C with continuous temperature monitoring and importer-of-record handling.
- 5 Arrival & dosing.** Treating centre administers SC injection every three weeks; dose titration guided by response and transfusion burden.

## Indicative economics

**Reference US cash-pay range:** USD 150,000–300,000 annualised at US list, weight-based (Reserve Meds provides a transparent delivered quote at intake).

## Indicative first-dose timing

**7–14 days** from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your haematologist and SFDA review, keyed to the erythroid-maturation-agent rationale. **Logistics.** Cold-chain (2–8°C) shipment with continuous temperature monitoring and importer-of-record handling. **Concierge case lead.** Named point of contact for family and care team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Reblozyl × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/reblozyl-saudi-arabia.html](https://reservemed.com/access-guides/reblozyl-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team